Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
about
Near IR heptamethine cyanine dye-mediated cancer imagingTumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome.Self-assembled lipid nanomedicines for siRNA tumor targeting.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Integrin alpha(v)beta(3)-Targeted Cancer Therapy.Aminopeptidase N (CD13) as a target for cancer chemotherapy.Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.Targeting angiogenesis for controlling neuroblastoma.Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells.Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironmentPhage Peptide Libraries As a Source of Targeted Ligands.RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.The neovasculature homing motif NGR: more than meets the eye.Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.Tumour vasculature targeting agents in hybrid/conjugate drugs.Therapies currently in Phase II trials for malignant pleural mesothelioma.Barriers to drug delivery in solid tumors.Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues.Lipid composition has significant effect on targeted drug delivery properties of NGR-modified liposomes.Building Cell Selectivity into CPP-Mediated Strategies.Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.Structure and activity of CPNGRC: a modified CD13/APN peptidic homing motif.Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain(99m)Tc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice.
P2860
Q24616262-A1185E62-8BEE-47F6-B42C-4B9B7AFB795DQ33325343-28B41F48-1D66-4BCB-9A16-77B5BA2696DFQ33762115-180589E3-24A2-41EC-9FEC-222508477E06Q33907953-848ED79B-2B1B-4834-A91A-F844A373AC7FQ33960866-9BE4E354-2391-4562-A634-F9D70D5FBEDAQ33983773-D9A691F9-F799-47E7-A37B-B9DF5F31475BQ34157418-F5AE73FC-D176-4C2D-83CF-6740D21BD9C1Q34253748-DAFB6424-F63A-4856-B3DF-03EFE8BB7153Q34271190-3EF222B9-426E-429B-9128-A8AD1F7F24D4Q34730638-54FA20C6-DBCA-4077-BF71-163F695CB4FAQ35184831-D67A4850-E96B-4821-A78C-358FF7FD5F19Q35742215-05021592-3A96-4FB6-8B6A-B01E8D61E4FDQ35749834-FBEE754C-E6DE-4C49-97EC-EDDEFCFE07D6Q35995567-5644BF15-D738-484A-BF0A-3F8EC80B71F9Q37134454-5394303E-E7B5-4AD2-86B0-4A9E73809181Q37198343-2CD1AF24-AE6C-41F2-96F5-0D15D696942FQ37287413-8BABC0A2-A223-48B5-B214-68E33EF69942Q38094627-0889BBC7-C389-4DA1-A630-819F830953A2Q38118385-0BCF1B66-52E3-4222-96F6-366DC0A0384BQ38234567-0B055255-CA5F-490B-BBF8-88F8D6D7D809Q38435415-D1A30C63-5268-40BA-8436-9D74AD50B008Q38819807-CEA0C263-3C49-4A40-8125-CEE700B67E4CQ38835070-A34712BF-CC86-4A8B-B164-2FC1D1CF50DFQ38974301-7CC2813B-7542-485B-9CBE-5F6808A3D5CCQ39173092-BCD1C138-11F5-4B50-BF37-D0973D5FAA31Q39752739-212F85B8-B9F5-40D0-B8AE-FCC841FA0827Q41328865-0E171A76-5FDC-4AC8-9496-0DE970E950AAQ41981559-34872B27-8AA1-47EE-BB22-7414ABADF68FQ46432247-FF171487-7165-4CDB-8135-A53867933922
P2860
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
@ast
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
@en
type
label
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
@ast
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
@en
prefLabel
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
@ast
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
@en
P356
P1476
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
@en
P304
P356
10.1196/ANNALS.1322.011
P407
P577
2004-12-01T00:00:00Z